Mesenchymal Stem Cell Transplantation Attenuates Brain Injury After Neonatal Stroke
Brain injury caused by stroke is a frequent cause of perinatal morbidity and mortality with limited therapeutic options. Mesenchymal stem cells (MSC) have been shown to improve outcome after neonatal hypoxic-ischemic brain injury mainly by secretion of growth factors stimulating repair processes. We...
Saved in:
Published in | Stroke (1970) Vol. 44; no. 5; pp. 1426 - 1432 |
---|---|
Main Authors | , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Hagerstown, MD
Lippincott Williams & Wilkins
01.05.2013
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Brain injury caused by stroke is a frequent cause of perinatal morbidity and mortality with limited therapeutic options. Mesenchymal stem cells (MSC) have been shown to improve outcome after neonatal hypoxic-ischemic brain injury mainly by secretion of growth factors stimulating repair processes. We investigated whether MSC treatment improves recovery after neonatal stroke and whether MSC overexpressing brain-derived neurotrophic factor (MSC-BDNF) further enhances recovery.
We performed 1.5-hour transient middle cerebral artery occlusion in 10-day-old rats. Three days after reperfusion, pups with evidence of injury by diffusion-weighted MRI were treated intranasally with MSC, MSC-BDNF, or vehicle. To determine the effect of MSC treatment, brain damage, sensorimotor function, and cerebral cell proliferation were analyzed.
Intranasal delivery of MSC- and MSC-BDNF significantly reduced infarct size and gray matter loss in comparison with vehicle-treated rats without any significant difference between MSC- and MSC-BDNF-treatment. Treatment with MSC-BDNF significantly reduced white matter loss with no significant difference between MSC- and MSC-BDNF-treatment. Motor deficits were also improved by MSC treatment when compared with vehicle-treated rats. MSC-BDNF-treatment resulted in an additional significant improvement of motor deficits 14 days after middle cerebral artery occlusion, but there was no significant difference between MSC or MSC-BDNF 28 days after middle cerebral artery occlusion. Furthermore, treatment with either MSC or MSC-BDNF induced long-lasting cell proliferation in the ischemic hemisphere.
Intranasal administration of MSC after neonatal stroke is a promising therapy for treatment of neonatal stroke. In this experimental paradigm, MSC- and BNDF-hypersecreting MSC are equally effective in reducing ischemic brain damage. |
---|---|
AbstractList | BACKGROUND AND PURPOSEBrain injury caused by stroke is a frequent cause of perinatal morbidity and mortality with limited therapeutic options. Mesenchymal stem cells (MSC) have been shown to improve outcome after neonatal hypoxic-ischemic brain injury mainly by secretion of growth factors stimulating repair processes. We investigated whether MSC treatment improves recovery after neonatal stroke and whether MSC overexpressing brain-derived neurotrophic factor (MSC-BDNF) further enhances recovery. METHODSWe performed 1.5-hour transient middle cerebral artery occlusion in 10-day-old rats. Three days after reperfusion, pups with evidence of injury by diffusion-weighted MRI were treated intranasally with MSC, MSC-BDNF, or vehicle. To determine the effect of MSC treatment, brain damage, sensorimotor function, and cerebral cell proliferation were analyzed. RESULTSIntranasal delivery of MSC- and MSC-BDNF significantly reduced infarct size and gray matter loss in comparison with vehicle-treated rats without any significant difference between MSC- and MSC-BDNF-treatment. Treatment with MSC-BDNF significantly reduced white matter loss with no significant difference between MSC- and MSC-BDNF-treatment. Motor deficits were also improved by MSC treatment when compared with vehicle-treated rats. MSC-BDNF-treatment resulted in an additional significant improvement of motor deficits 14 days after middle cerebral artery occlusion, but there was no significant difference between MSC or MSC-BDNF 28 days after middle cerebral artery occlusion. Furthermore, treatment with either MSC or MSC-BDNF induced long-lasting cell proliferation in the ischemic hemisphere. CONCLUSIONSIntranasal administration of MSC after neonatal stroke is a promising therapy for treatment of neonatal stroke. In this experimental paradigm, MSC- and BNDF-hypersecreting MSC are equally effective in reducing ischemic brain damage. Background and Purpose— Brain injury caused by stroke is a frequent cause of perinatal morbidity and mortality with limited therapeutic options. Mesenchymal stem cells (MSC) have been shown to improve outcome after neonatal hypoxic-ischemic brain injury mainly by secretion of growth factors stimulating repair processes. We investigated whether MSC treatment improves recovery after neonatal stroke and whether MSC overexpressing brain-derived neurotrophic factor (MSC-BDNF) further enhances recovery. Methods— We performed 1.5-hour transient middle cerebral artery occlusion in 10-day-old rats. Three days after reperfusion, pups with evidence of injury by diffusion-weighted MRI were treated intranasally with MSC, MSC-BDNF, or vehicle. To determine the effect of MSC treatment, brain damage, sensorimotor function, and cerebral cell proliferation were analyzed. Results— Intranasal delivery of MSC- and MSC-BDNF significantly reduced infarct size and gray matter loss in comparison with vehicle-treated rats without any significant difference between MSC- and MSC-BDNF–treatment. Treatment with MSC-BDNF significantly reduced white matter loss with no significant difference between MSC- and MSC-BDNF–treatment. Motor deficits were also improved by MSC treatment when compared with vehicle-treated rats. MSC-BDNF–treatment resulted in an additional significant improvement of motor deficits 14 days after middle cerebral artery occlusion, but there was no significant difference between MSC or MSC-BDNF 28 days after middle cerebral artery occlusion. Furthermore, treatment with either MSC or MSC-BDNF induced long-lasting cell proliferation in the ischemic hemisphere. Conclusions— Intranasal administration of MSC after neonatal stroke is a promising therapy for treatment of neonatal stroke. In this experimental paradigm, MSC- and BNDF-hypersecreting MSC are equally effective in reducing ischemic brain damage. Brain injury caused by stroke is a frequent cause of perinatal morbidity and mortality with limited therapeutic options. Mesenchymal stem cells (MSC) have been shown to improve outcome after neonatal hypoxic-ischemic brain injury mainly by secretion of growth factors stimulating repair processes. We investigated whether MSC treatment improves recovery after neonatal stroke and whether MSC overexpressing brain-derived neurotrophic factor (MSC-BDNF) further enhances recovery. We performed 1.5-hour transient middle cerebral artery occlusion in 10-day-old rats. Three days after reperfusion, pups with evidence of injury by diffusion-weighted MRI were treated intranasally with MSC, MSC-BDNF, or vehicle. To determine the effect of MSC treatment, brain damage, sensorimotor function, and cerebral cell proliferation were analyzed. Intranasal delivery of MSC- and MSC-BDNF significantly reduced infarct size and gray matter loss in comparison with vehicle-treated rats without any significant difference between MSC- and MSC-BDNF-treatment. Treatment with MSC-BDNF significantly reduced white matter loss with no significant difference between MSC- and MSC-BDNF-treatment. Motor deficits were also improved by MSC treatment when compared with vehicle-treated rats. MSC-BDNF-treatment resulted in an additional significant improvement of motor deficits 14 days after middle cerebral artery occlusion, but there was no significant difference between MSC or MSC-BDNF 28 days after middle cerebral artery occlusion. Furthermore, treatment with either MSC or MSC-BDNF induced long-lasting cell proliferation in the ischemic hemisphere. Intranasal administration of MSC after neonatal stroke is a promising therapy for treatment of neonatal stroke. In this experimental paradigm, MSC- and BNDF-hypersecreting MSC are equally effective in reducing ischemic brain damage. |
Author | KAVELAARS, Annemieke DERUGIN, Nikita MAAS, Mirjam HEIJNEN, Cobi J FERRIERO, Donna M SHELDON, R. Ann VEXLER, Zinaida S VELTHOVEN, Cindy T. J. Van WILLEMEN, Hanneke L. D. M |
AuthorAffiliation | 2 Departments of Neurology and Pediatrics, University of California San Francisco, San Francisco, CA, USA 3 Department of Symptom Research, University of Texas, MD Anderson Cancer Centre, Houston, TX, USA 1 Laboratory of Neuroimmunology and Developmental Origins of Disease, University Medical Center Utrecht, Utrecht, the Netherlands |
AuthorAffiliation_xml | – name: 2 Departments of Neurology and Pediatrics, University of California San Francisco, San Francisco, CA, USA – name: 1 Laboratory of Neuroimmunology and Developmental Origins of Disease, University Medical Center Utrecht, Utrecht, the Netherlands – name: 3 Department of Symptom Research, University of Texas, MD Anderson Cancer Centre, Houston, TX, USA |
Author_xml | – sequence: 1 givenname: Cindy T. J. Van surname: VELTHOVEN fullname: VELTHOVEN, Cindy T. J. Van organization: Laboratory of Neuroimmunology and Developmental Origins of Disease, University Medical Center Utrecht, Utrecht, Netherlands – sequence: 2 givenname: R. Ann surname: SHELDON fullname: SHELDON, R. Ann organization: Department of Neurology and Pediatrics, University of California San Francisco, San Francisco, CA, United States – sequence: 3 givenname: Annemieke surname: KAVELAARS fullname: KAVELAARS, Annemieke organization: Department of Symptom Research, University of Texas, MD Anderson Cancer Centre, Houston, TX, United States – sequence: 4 givenname: Nikita surname: DERUGIN fullname: DERUGIN, Nikita organization: Department of Neurology and Pediatrics, University of California San Francisco, San Francisco, CA, United States – sequence: 5 givenname: Zinaida S surname: VEXLER fullname: VEXLER, Zinaida S organization: Department of Neurology and Pediatrics, University of California San Francisco, San Francisco, CA, United States – sequence: 6 givenname: Hanneke L. D. M surname: WILLEMEN fullname: WILLEMEN, Hanneke L. D. M organization: Laboratory of Neuroimmunology and Developmental Origins of Disease, University Medical Center Utrecht, Utrecht, Netherlands – sequence: 7 givenname: Mirjam surname: MAAS fullname: MAAS, Mirjam organization: Laboratory of Neuroimmunology and Developmental Origins of Disease, University Medical Center Utrecht, Utrecht, Netherlands – sequence: 8 givenname: Cobi J surname: HEIJNEN fullname: HEIJNEN, Cobi J organization: Laboratory of Neuroimmunology and Developmental Origins of Disease, University Medical Center Utrecht, Utrecht, Netherlands – sequence: 9 givenname: Donna M surname: FERRIERO fullname: FERRIERO, Donna M organization: Department of Neurology and Pediatrics, University of California San Francisco, San Francisco, CA, United States |
BackLink | http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=27321628$$DView record in Pascal Francis https://www.ncbi.nlm.nih.gov/pubmed/23539530$$D View this record in MEDLINE/PubMed |
BookMark | eNpVkU9vEzEQxS1URNPCN0BoL0hctvh_1hekJSq0olCJhLM1cWbJll07tb1I-fa4JBQ4Wc_-zfPMvDNy4oNHQl4yesGYZm9TjuEHwhaKZBeUUsH1EzJjistaat6ckFm5MzWXxpySs5TuCsNFo56RUy6UMErQGVl-xoTebfcjDNUy41gtcBiqVQSfdgP4DLkPvmpzRj9BxlS9j9D76trfTXFftV3GWH3B4CH_Nnjo6Tl52sGQ8MXxPCffPlyuFlf1ze3H60V7UzulVK411-iocs5w46CBTaea9Zw2Dd9IMEIopnWnRVeUYwbXHQdHJQXYrOcdIohz8u7gu5vWI24c-hxhsLvYjxD3NkBv_3_x_dZ-Dz-t0EZKIYrBm6NBDPcTpmzHPrkyP3gMU7JMSKVY08xVQeUBdTGkFLF7_IZR-5CHXa6-3n66bK_aIpk95FHKXv3b4mPRnwAK8PoIQHIwdGXvrk9_ubngrIQpfgGbTJl2 |
CODEN | SJCCA7 |
CitedBy_id | crossref_primary_10_3233_JAD_170057 crossref_primary_10_3390_ijms21114051 crossref_primary_10_1007_s00216_013_7526_5 crossref_primary_10_1038_jcbfm_2014_41 crossref_primary_10_3390_ijms222111395 crossref_primary_10_1016_j_neuropharm_2016_03_052 crossref_primary_10_1038_s41390_018_0142_5 crossref_primary_10_1007_s12975_016_0482_6 crossref_primary_10_1016_j_spen_2019_08_009 crossref_primary_10_3389_fphys_2019_00540 crossref_primary_10_4103_1673_5374_310942 crossref_primary_10_1016_j_clineuro_2018_07_013 crossref_primary_10_1002_sctm_21_0243 crossref_primary_10_1016_j_nbd_2016_02_011 crossref_primary_10_2174_1574888X15666200628141314 crossref_primary_10_1016_j_bbi_2022_10_017 crossref_primary_10_1080_08820139_2020_1801720 crossref_primary_10_1021_acs_bioconjchem_2c00305 crossref_primary_10_1002_cbf_3957 crossref_primary_10_1038_s41390_019_0425_5 crossref_primary_10_3389_fvets_2022_958724 crossref_primary_10_3389_fcell_2020_00737 crossref_primary_10_1155_2018_9652897 crossref_primary_10_1186_scrt546 crossref_primary_10_5966_sctm_2015_0372 crossref_primary_10_1038_mt_2013_260 crossref_primary_10_1038_srep18587 crossref_primary_10_1007_s12035_015_9107_4 crossref_primary_10_1007_s12015_013_9492_x crossref_primary_10_3390_ijms241914434 crossref_primary_10_1016_j_jcyt_2020_06_002 crossref_primary_10_1111_jnc_15267 crossref_primary_10_1016_j_bioactmat_2022_11_007 crossref_primary_10_1016_j_expneurol_2018_07_006 crossref_primary_10_1016_j_nbd_2018_10_006 crossref_primary_10_1016_j_jcyt_2019_04_055 crossref_primary_10_1016_S1474_4422_22_00142_9 crossref_primary_10_1002_glia_23939 crossref_primary_10_1016_j_expneurol_2024_114701 crossref_primary_10_1089_scd_2014_0076 crossref_primary_10_3390_ijms22063142 crossref_primary_10_5853_jos_2019_03048 crossref_primary_10_3389_fneur_2020_601286 crossref_primary_10_1038_s41598_017_10406_x crossref_primary_10_3727_096368915X686887 crossref_primary_10_3390_ph13020031 crossref_primary_10_4252_wjsc_v15_i4_196 crossref_primary_10_1016_j_pneurobio_2013_11_007 crossref_primary_10_1186_s13287_020_1582_5 crossref_primary_10_1002_stem_1802 crossref_primary_10_3233_NPM_200477 crossref_primary_10_1016_j_mri_2021_03_008 crossref_primary_10_1016_j_bbrc_2018_05_086 crossref_primary_10_1186_s41232_016_0032_3 crossref_primary_10_1016_j_nbd_2016_04_006 crossref_primary_10_1016_j_pediatrneurol_2015_01_016 crossref_primary_10_1016_j_intimp_2020_106463 crossref_primary_10_3171_2014_10_SPINE14690 crossref_primary_10_2147_IJN_S278687 crossref_primary_10_1007_s10571_021_01145_9 crossref_primary_10_1089_hum_2020_319 crossref_primary_10_1093_stcltm_szac005 crossref_primary_10_1016_j_drudis_2022_103371 crossref_primary_10_1038_cddis_2017_184 crossref_primary_10_3390_cancers13051169 crossref_primary_10_1016_j_semperi_2023_151730 crossref_primary_10_3389_fbioe_2020_00043 crossref_primary_10_1186_s12868_018_0418_z crossref_primary_10_1016_j_neuroscience_2014_01_018 crossref_primary_10_1002_elsc_201800015 crossref_primary_10_1186_s11671_021_03540_z crossref_primary_10_1002_brb3_526 crossref_primary_10_1093_eurheartj_eht183 crossref_primary_10_1007_s40291_020_00491_6 crossref_primary_10_3727_096368916X692861 crossref_primary_10_3389_fnins_2024_1383941 crossref_primary_10_1038_pr_2017_243 crossref_primary_10_1038_s41572_022_00337_x crossref_primary_10_1038_pr_2017_249 crossref_primary_10_1038_s41598_019_42182_1 crossref_primary_10_1159_000444905 crossref_primary_10_18632_oncotarget_16778 crossref_primary_10_1016_j_bbi_2016_11_011 crossref_primary_10_1016_j_neurop_2021_07_004 crossref_primary_10_1111_zph_12138 crossref_primary_10_1007_s00192_022_05439_4 crossref_primary_10_1002_sctm_19_0174 crossref_primary_10_1093_brain_awac393 crossref_primary_10_1016_j_brainresbull_2020_09_018 crossref_primary_10_1002_sctm_18_0284 crossref_primary_10_1016_j_yexcr_2023_113734 crossref_primary_10_1016_j_braindev_2023_09_001 crossref_primary_10_1016_j_semperi_2024_151929 crossref_primary_10_1016_j_brainres_2014_07_016 crossref_primary_10_1016_j_brainres_2013_07_037 crossref_primary_10_1002_jnr_24548 crossref_primary_10_1080_17425247_2019_1645116 crossref_primary_10_1038_pr_2017_233 crossref_primary_10_1155_2020_8822579 crossref_primary_10_3389_fneur_2022_1000777 crossref_primary_10_1111_apha_13674 crossref_primary_10_1016_j_imlet_2015_08_007 crossref_primary_10_1053_j_semperi_2015_12_002 crossref_primary_10_1161_STROKEAHA_120_031191 crossref_primary_10_1259_bjr_20150806 crossref_primary_10_14348_molcells_2014_0010 crossref_primary_10_1017_S1047951122002633 crossref_primary_10_3390_ijms20153747 crossref_primary_10_3727_096368915X686201 crossref_primary_10_1016_j_neuropharm_2015_06_008 crossref_primary_10_1186_s12974_019_1571_8 crossref_primary_10_1002_adfm_201900603 crossref_primary_10_1111_cns_13378 crossref_primary_10_1016_j_jns_2015_03_014 crossref_primary_10_18632_oncotarget_22155 crossref_primary_10_3390_brainsci5020165 crossref_primary_10_3892_mmr_2014_2805 crossref_primary_10_1016_j_pediatrneurol_2019_02_016 crossref_primary_10_1016_S2352_4642_18_30173_1 crossref_primary_10_1039_D3LC00379E crossref_primary_10_1177_0963689717728936 crossref_primary_10_1177_0963689718795424 crossref_primary_10_1016_j_actbio_2014_11_027 crossref_primary_10_1016_j_bcp_2021_114461 crossref_primary_10_1016_j_jcyt_2021_03_005 crossref_primary_10_1161_STROKEAHA_123_043399 crossref_primary_10_1016_j_addr_2019_10_005 crossref_primary_10_1007_s12975_022_01111_7 crossref_primary_10_2174_1574888X17666220425102154 crossref_primary_10_1016_j_jcyt_2015_07_019 crossref_primary_10_3390_cells10081992 crossref_primary_10_7874_jao_2018_00115 crossref_primary_10_2174_1570159X20666220222144744 crossref_primary_10_3390_neurolint15030057 crossref_primary_10_1007_s13311_021_01076_9 crossref_primary_10_3389_fneur_2020_568814 crossref_primary_10_3389_fnins_2014_00359 crossref_primary_10_3390_ijms21113807 crossref_primary_10_1002_jnr_23954 crossref_primary_10_1007_s10753_024_02005_6 crossref_primary_10_4103_1673_5374_208547 crossref_primary_10_1016_j_jcyt_2020_01_009 crossref_primary_10_3389_fneur_2018_00133 crossref_primary_10_1515_revneuro_2021_0163 crossref_primary_10_1038_s41390_022_02208_3 crossref_primary_10_1016_j_clp_2013_09_002 |
Cites_doi | 10.1073/pnas.0803670105 10.1161/strokeaha.106.477331 10.1038/nrn3379 10.1016/j.bbi.2009.10.017 10.1111/j.1440-1789.2007.00792.x 10.1038/pr.2012.71 10.1159/000232558 10.1161/strokeaha.108.531806 10.1016/j.bbrc.2005.05.055 10.1002/ana.21068 10.1056/NEJMra041996 10.1016/S0168-0102(98)00096-0 10.1203/PDR.0b013e31821d0d00 10.1016/S0022-510X(01)00557-3 10.1523/JNEUROSCI.2102-11.2011 10.3727/096368908787236576 10.1016/j.neuron.2011.05.001 10.1016/j.bbi.2011.03.021 10.1159/000046140 10.1016/S1474-4422(09)70061-4 10.1016/0896-6273(93)90311-E 10.1016/j.bbi.2009.09.008 10.1371/journal.pone.0051253 10.1016/j.neuroscience.2010.10.054 10.1523/JNEUROSCI.1835-10.2010 10.1016/j.pediatrneurol.2008.09.018 |
ContentType | Journal Article |
Copyright | 2014 INIST-CNRS |
Copyright_xml | – notice: 2014 INIST-CNRS |
DBID | IQODW CGR CUY CVF ECM EIF NPM AAYXX CITATION 7X8 5PM |
DOI | 10.1161/strokeaha.111.000326 |
DatabaseName | Pascal-Francis Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef MEDLINE - Academic PubMed Central (Full Participant titles) |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef MEDLINE - Academic |
DatabaseTitleList | MEDLINE - Academic CrossRef MEDLINE |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1524-4628 |
EndPage | 1432 |
ExternalDocumentID | 10_1161_STROKEAHA_111_000326 23539530 27321628 |
Genre | Research Support, Non-U.S. Gov't Journal Article Research Support, N.I.H., Extramural |
GrantInformation_xml | – fundername: NINDS NIH HHS grantid: NS35902 – fundername: NINDS NIH HHS grantid: P50 NS035902 – fundername: NINDS NIH HHS grantid: R01 NS076726 – fundername: NINDS NIH HHS grantid: R01 NS044025 – fundername: NINDS NIH HHS grantid: R01 NS033997 – fundername: National Institute of Neurological Disorders and Stroke : NINDS grantid: P50 NS035902 || NS |
GroupedDBID | --- .3C .55 .GJ .XZ .Z2 01R 08R 0R~ 123 1J1 2WC 3O- 40H 4Q1 4Q2 4Q3 53G 5RE 5VS 6PF 71W 77Y 7O~ A9M AAAXR AAGIX AAHPQ AAJCS AAMOA AAMTA AAPBV AAQKA AAQQT AARTV AASOK AAXQO AAYEP AAYJJ ABASU ABBUW ABDIG ABFLS ABQRW ABXVJ ABZAD ACCJW ACDDN ACEWG ACGFS ACGOD ACWDW ACWRI ACXNZ ADBBV ADFPA ADGIM ADNKB AE3 AE6 AEBDS AENEX AFDTB AFFNX AFUWQ AGINI AHMBA AHRYX AHVBC AIJEX AJIOK AJNYG AKULP ALMA_UNASSIGNED_HOLDINGS ALMTX AMJPA AMKUR AWKKM AYCSE BAWUL BCGUY BOYCO BQLVK BS7 C45 CS3 DIK DIWNM DU5 DUNZO E.X E3Z EBS EJD EX3 F2K F2L F2M F2N F5P FL- FW0 GQDEL GX1 H0~ H13 HZ~ IKREB IKYAY IN~ IPNFZ IQODW J5H JF9 JG8 JK3 JK8 K8S KD2 KMI KQ8 L-C L7B M18 N4W N9A N~7 N~B N~M O9- OAG OAH OB3 OCUKA ODA ODMTH OGROG OHYEH OJAPA OK1 OL1 OLG OLH OLU OLV OLW OLY OLZ OPUJH ORVUJ OUVQU OVD OVDNE OVIDH OVLEI OVOZU OWBYB OWU OWV OWW OWX OWY OWZ OXXIT P-K P2P PQEST PQQKQ R58 RAH RHF RIG RLZ S4R S4S T8P TEORI TSPGW TWZ V2I VVN W3M W8F WH7 WOQ WOW X3V X3W X7M XXN XYM YCJ YFH YHZ YQJ YYP ZA5 ZB8 ZGI ZZMQN AAAAV AAIQE AASCR AAUEB ABJNI ABVCZ ACILI ACXJB ADGGA ADHPY AEETU AFEXH AFSOK AHOMT AHQNM AINUH AJNWD AJZMW AMNEI AOHHW CGR CUY CVF ECM EEVPB EIF ERAAH FCALG GNXGY HLJTE NPM AAYXX CITATION 7X8 5PM |
ID | FETCH-LOGICAL-c555t-626ec05cc929ca8adf58b70882d4a9335166f63fd4ac19ebf2ac040aadb7feea3 |
ISSN | 0039-2499 |
IngestDate | Tue Sep 17 21:22:13 EDT 2024 Fri Aug 16 08:26:59 EDT 2024 Fri Aug 23 01:48:42 EDT 2024 Sat Sep 28 07:51:04 EDT 2024 Fri Nov 25 13:52:52 EST 2022 |
IsDoiOpenAccess | false |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 5 |
Keywords | Human neonatal stroke postnatal Stroke Nervous system diseases Brain stem Cardiovascular disease Cerebral disorder Vascular disease cell transplantation Newborn cerebral ischemia mesenchymal stem cells Central nervous system disease Brain ischemia Cerebrovascular disease |
Language | English |
License | CC BY 4.0 |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c555t-626ec05cc929ca8adf58b70882d4a9335166f63fd4ac19ebf2ac040aadb7feea3 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
OpenAccessLink | https://www.ahajournals.org/doi/pdf/10.1161/STROKEAHA.111.000326 |
PMID | 23539530 |
PQID | 1345518875 |
PQPubID | 23479 |
PageCount | 7 |
ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_3694433 proquest_miscellaneous_1345518875 crossref_primary_10_1161_STROKEAHA_111_000326 pubmed_primary_23539530 pascalfrancis_primary_27321628 |
PublicationCentury | 2000 |
PublicationDate | 2013-05-01 |
PublicationDateYYYYMMDD | 2013-05-01 |
PublicationDate_xml | – month: 05 year: 2013 text: 2013-05-01 day: 01 |
PublicationDecade | 2010 |
PublicationPlace | Hagerstown, MD |
PublicationPlace_xml | – name: Hagerstown, MD – name: United States |
PublicationTitle | Stroke (1970) |
PublicationTitleAlternate | Stroke |
PublicationYear | 2013 |
Publisher | Lippincott Williams & Wilkins |
Publisher_xml | – name: Lippincott Williams & Wilkins |
References | 20631189 - J Neurosci. 2010 Jul 14;30(28):9603-11 8439409 - Neuron. 1993 Feb;10(2):201-12 19375666 - Lancet Neurol. 2009 May;8(5):491-500 21034794 - Neuroscience. 2011 Jan 13;172:398-405 21609825 - Neuron. 2011 May 26;70(4):687-702 23254191 - Nat Rev Neurosci. 2013 Jan;14(1):7-23 21473911 - Brain Behav Immun. 2011 Oct;25(7):1342-8 22669296 - Pediatr Res. 2012 Sep;72(3):277-84 17286251 - Ann Neurol. 2007 Mar;61(3):199-208 21900578 - J Neurosci. 2011 Sep 7;31(36):12992-3001 9950062 - Neurosci Res. 1998 Dec;32(4):349-53 11535233 - J Neurol Sci. 2001 Aug 15;189(1-2):49-57 19766183 - Brain Behav Immun. 2010 Jul;24(5):812-21 19218034 - Pediatr Neurol. 2009 Mar;40(3):205-14 19672069 - Dev Neurosci. 2009;31(5):403-11 20639794 - Pediatr Res. 2010 Nov;68(5):419-22 17899689 - Neuropathology. 2007 Aug;27(4):355-63 15525724 - N Engl J Med. 2004 Nov 4;351(19):1985-95 19164786 - Stroke. 2009 Apr;40(4):1490-5 11598317 - Dev Neurosci. 2001;23(3):180-5 19883750 - Brain Behav Immun. 2010 Mar;24(3):387-93 15922299 - Biochem Biophys Res Commun. 2005 Jul 15;332(4):1101-6 18794523 - Proc Natl Acad Sci U S A. 2008 Sep 23;105(38):14638-43 23300948 - PLoS One. 2013;8(1):e51253 19181205 - Cell Transplant. 2008;17(10-11):1103-13 21659957 - Pediatr Res. 2011 Jul;70(1):3-9 17510456 - Stroke. 2007 Jul;38(7):2165-72 e_1_3_3_17_2 e_1_3_3_16_2 e_1_3_3_19_2 e_1_3_3_18_2 e_1_3_3_13_2 e_1_3_3_12_2 e_1_3_3_15_2 e_1_3_3_14_2 e_1_3_3_10_2 e_1_3_3_6_2 van Velthoven CT (e_1_3_3_11_2) 2010; 68 e_1_3_3_5_2 e_1_3_3_8_2 e_1_3_3_7_2 e_1_3_3_28_2 e_1_3_3_9_2 e_1_3_3_27_2 e_1_3_3_24_2 e_1_3_3_23_2 e_1_3_3_26_2 e_1_3_3_25_2 e_1_3_3_2_2 e_1_3_3_20_2 e_1_3_3_4_2 e_1_3_3_22_2 e_1_3_3_3_2 e_1_3_3_21_2 |
References_xml | – ident: e_1_3_3_17_2 doi: 10.1073/pnas.0803670105 – ident: e_1_3_3_24_2 doi: 10.1161/strokeaha.106.477331 – ident: e_1_3_3_26_2 doi: 10.1038/nrn3379 – volume: 68 start-page: 419 year: 2010 ident: e_1_3_3_11_2 article-title: Nasal administration of stem cells: a promising novel route to treat neonatal ischemic brain damage. publication-title: Pediatr Res contributor: fullname: van Velthoven CT – ident: e_1_3_3_5_2 doi: 10.1016/j.bbi.2009.10.017 – ident: e_1_3_3_7_2 doi: 10.1111/j.1440-1789.2007.00792.x – ident: e_1_3_3_16_2 doi: 10.1038/pr.2012.71 – ident: e_1_3_3_22_2 doi: 10.1159/000232558 – ident: e_1_3_3_25_2 doi: 10.1161/strokeaha.108.531806 – ident: e_1_3_3_9_2 doi: 10.1016/j.bbrc.2005.05.055 – ident: e_1_3_3_20_2 doi: 10.1002/ana.21068 – ident: e_1_3_3_2_2 doi: 10.1056/NEJMra041996 – ident: e_1_3_3_10_2 doi: 10.1016/S0168-0102(98)00096-0 – ident: e_1_3_3_27_2 doi: 10.1203/PDR.0b013e31821d0d00 – ident: e_1_3_3_4_2 doi: 10.1016/S0022-510X(01)00557-3 – ident: e_1_3_3_13_2 doi: 10.1523/JNEUROSCI.2102-11.2011 – ident: e_1_3_3_15_2 doi: 10.3727/096368908787236576 – ident: e_1_3_3_28_2 doi: 10.1016/j.neuron.2011.05.001 – ident: e_1_3_3_6_2 doi: 10.1016/j.bbi.2011.03.021 – ident: e_1_3_3_18_2 doi: 10.1159/000046140 – ident: e_1_3_3_14_2 doi: 10.1016/S1474-4422(09)70061-4 – ident: e_1_3_3_19_2 doi: 10.1016/0896-6273(93)90311-E – ident: e_1_3_3_12_2 doi: 10.1016/j.bbi.2009.09.008 – ident: e_1_3_3_21_2 doi: 10.1371/journal.pone.0051253 – ident: e_1_3_3_23_2 doi: 10.1016/j.neuroscience.2010.10.054 – ident: e_1_3_3_8_2 doi: 10.1523/JNEUROSCI.1835-10.2010 – ident: e_1_3_3_3_2 doi: 10.1016/j.pediatrneurol.2008.09.018 |
SSID | ssj0002385 |
Score | 2.5344825 |
Snippet | Brain injury caused by stroke is a frequent cause of perinatal morbidity and mortality with limited therapeutic options. Mesenchymal stem cells (MSC) have been... Background and Purpose— Brain injury caused by stroke is a frequent cause of perinatal morbidity and mortality with limited therapeutic options. Mesenchymal... BACKGROUND AND PURPOSEBrain injury caused by stroke is a frequent cause of perinatal morbidity and mortality with limited therapeutic options. Mesenchymal stem... |
SourceID | pubmedcentral proquest crossref pubmed pascalfrancis |
SourceType | Open Access Repository Aggregation Database Index Database |
StartPage | 1426 |
SubjectTerms | Animals Biological and medical sciences Brain - pathology Brain-Derived Neurotrophic Factor - therapeutic use Cell Proliferation Disease Models, Animal Headache. Facial pains. Syncopes. Epilepsia. Intracranial hypertension. Brain oedema. Cerebral palsy Infarction, Middle Cerebral Artery - drug therapy Infarction, Middle Cerebral Artery - pathology Infarction, Middle Cerebral Artery - therapy Medical sciences Mesenchymal Stem Cell Transplantation - methods Nerve Fibers, Myelinated - pathology Nervous system (semeiology, syndromes) Neurology Neurons - metabolism Rats Rats, Sprague-Dawley Stroke - pathology Stroke - therapy Vascular diseases and vascular malformations of the nervous system |
Title | Mesenchymal Stem Cell Transplantation Attenuates Brain Injury After Neonatal Stroke |
URI | https://www.ncbi.nlm.nih.gov/pubmed/23539530 https://search.proquest.com/docview/1345518875 https://pubmed.ncbi.nlm.nih.gov/PMC3694433 |
Volume | 44 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3fb9MwELZgSAgJTfymAyYj8VZl1HWcNI_VGKqYOsTaob1FtuuspW1aremk8ddzZ7tNMooEvESt4ziy7_PlzvZ9R8gHBXOGCRUGCc94EIJBG3SyLAxa4N8KAxZ-pDE4uX8W9S7CL5fistzRtdElhTrSP3fGlfyPVKEM5IpRsv8g2W2jUAC_Qb5wBQnD9a9k3MfQIT2-ndugDzNv4jI8Zn3IV8uZzP1BQmTQzNdoUzYVJoRoTvIfMJI-PXhucP3cRY0sprWDQQNbYqmckrhVWTPAmKfvZlaMFzdOax2DZ3_bHFb2mMZm5tOEnDe7ebnVL2_MTEqXlw3KzXxipltsfTLX6ytHanA2mU4KWV2TYJUTgEfG69F2GGDYa1XROqJHDyhR0ZosdFHzv6vzCNW5678cS9TvSDjJ69VBKMu5FXGbC54Iv9FTp9He3LpPHrTjRKCffvqtJJYHy0X4yEp46cddr0TeaN9IzYh5vJQrmE-ZS4Syy1O5e-C2YsEMn5B973rQrsPRU3LP5M_Iw74_XPGcDCpwoggninCid-BESzhRCyfq4EQtnOgGTtT17QW5-HwyPO4FPudGoIUQRQD-rdEtoTWYzVp25CgTHRWjHzYKZcK5YFGURTyDf5olRmVtqeE7IOVIxZkxkr8ke_kiN68JFSOwXTuJbnWgBuNGRkpnUTJSSoJPwliDBJtBTJeOWiW1LmnE0sHw_OvpSbfXRQ81dePfIIe1kd4-BBZ4mwHWGuT9ZuhTUJI4RhJ6vV6ljIeWeTAWDfLKiaJ82su0QeKakLYVkIC9fiefjC0RO4-SMOT84I9tviGPyunxluwV12vzDozYQh1a-P0CeVCg1Q |
link.rule.ids | 230,315,786,790,891,27957,27958 |
linkProvider | Colorado Alliance of Research Libraries |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Mesenchymal+stem+cell+transplantation+attenuates+brain+injury+after+neonatal+stroke&rft.jtitle=Stroke+%281970%29&rft.au=van+Velthoven%2C+Cindy+T+J&rft.au=Sheldon%2C+R+Ann&rft.au=Kavelaars%2C+Annemieke&rft.au=Derugin%2C+Nikita&rft.date=2013-05-01&rft.eissn=1524-4628&rft.volume=44&rft.issue=5&rft.spage=1426&rft_id=info:doi/10.1161%2Fstrokeaha.111.000326&rft_id=info%3Apmid%2F23539530&rft.externalDocID=23539530 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0039-2499&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0039-2499&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0039-2499&client=summon |